Individualized cost-effectiveness analysis

[...]randomized trials and other clinical studies typically feed their data into decision and cost-effectiveness models. [...]the granularity of the cost and outcomes per patient may be important to convey, i.e., specifying separately the different outcomes, so that clinicians and patients may be be...

Full description

Saved in:
Bibliographic Details
Published in:PLoS medicine 2011-07, Vol.8 (7), p.e1001058-e1001058
Main Authors: Ioannidis, John P A, Garber, Alan M
Format: Article
Language:English
Subjects:
Analysis
Colds
Cost benefit analysis
Cost-Benefit Analysis - methods
Costs
Decision Making
Health aspects
Health Care Costs
Humans
Immunization
Intervention
Medical care, Cost of
Medicine
Models, Econometric
Population
Social and Behavioral Sciences
Social aspects
Studies
Treatment outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c763t-e88fc4f14b2fcb7c20913801ec589fe69bebc2b168a61049e3dc37a80e88e37b3
cites cdi_FETCH-LOGICAL-c763t-e88fc4f14b2fcb7c20913801ec589fe69bebc2b168a61049e3dc37a80e88e37b3
container_end_page e1001058
container_issue 7
container_start_page e1001058
container_title PLoS medicine
container_volume 8
creator Ioannidis, John P A
Garber, Alan M
description [...]randomized trials and other clinical studies typically feed their data into decision and cost-effectiveness models. [...]the granularity of the cost and outcomes per patient may be important to convey, i.e., specifying separately the different outcomes, so that clinicians and patients may be better informed and able to make better choices. Erroneous inferences may result from unrealistic modeling of the decision process or unrealistic estimates for the various benefits, harms, and costs. [...]uncertainty in these values [42] or even in risk aversion [43] should not be underestimated.
doi_str_mv 10.1371/journal.pmed.1001058
format article
fullrecord <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_1288093577</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A263785781</galeid><doaj_id>oai_doaj_org_article_3589721c6314427c83eb08dc5868889c</doaj_id><sourcerecordid>A263785781</sourcerecordid><originalsourceid>FETCH-LOGICAL-c763t-e88fc4f14b2fcb7c20913801ec589fe69bebc2b168a61049e3dc37a80e88e37b3</originalsourceid><addsrcrecordid>eNqVk9tq3DAQhk1padK0b1DaQKGlBW81lizJN4UQelgIDfR0K2R57NWitTaWvSR5-mq7TliXvWjRhcTo-_8ZaZgkeQ5kBlTA-6Ufula72XqF1QwIAZLLB8kx5KxIgQv-cO98lDwJYUlIVpCCPE6OMhA8l0COk3fztrIbWw3a2VusTo0PfYp1jaa3G2wxhFMds9wEG54mj2rtAj4b95Pk56ePP86_pBeXn-fnZxepEZxGsZS1YTWwMqtNKUxGCqCSAJpcFjXyosTSZCVwqTkQViCtDBVakihEKkp6krzc-a6dD2p8ZlCQSUkKmgsRifmOqLxeqnVnV7q7UV5b9Sfgu0bprrfGoaIxqcjAcAqMZcJIiiWRVayFSykLE70-jNmGMv6kwbbvtJuYTm9au1CN3ygKlDHOosGb0aDzVwOGXq1sMOicbtEPQUkhCYWMkUi--os8_LiRanSs37a1j2nN1lOdZZwKmQsJkUoPUE3sWKzRt1jbGJ7wswN8XBWurDkoeDsRRKbH677RQwhq_v3bf7Bf_529_DVlX--xC9SuXwTvht76NkxBtgNN50PosL7vHxC1nZa7n1bbaVHjtETZi_3e34vuxoP-BvQsDDs</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1288093577</pqid></control><display><type>article</type><title>Individualized cost-effectiveness analysis</title><source>NCBI_PubMed Central（免费）</source><source>ProQuest - Publicly Available Content Database</source><creator>Ioannidis, John P A ; Garber, Alan M</creator><creatorcontrib>Ioannidis, John P A ; Garber, Alan M</creatorcontrib><description>[...]randomized trials and other clinical studies typically feed their data into decision and cost-effectiveness models. [...]the granularity of the cost and outcomes per patient may be important to convey, i.e., specifying separately the different outcomes, so that clinicians and patients may be better informed and able to make better choices. Erroneous inferences may result from unrealistic modeling of the decision process or unrealistic estimates for the various benefits, harms, and costs. [...]uncertainty in these values [42] or even in risk aversion [43] should not be underestimated.</description><identifier>ISSN: 1549-1676</identifier><identifier>ISSN: 1549-1277</identifier><identifier>EISSN: 1549-1676</identifier><identifier>DOI: 10.1371/journal.pmed.1001058</identifier><identifier>PMID: 21765810</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Analysis ; Colds ; Cost benefit analysis ; Cost-Benefit Analysis - methods ; Costs ; Decision Making ; Health aspects ; Health Care Costs ; Humans ; Immunization ; Intervention ; Medical care, Cost of ; Medicine ; Models, Econometric ; Population ; Social and Behavioral Sciences ; Social aspects ; Studies ; Treatment outcome</subject><ispartof>PLoS medicine, 2011-07, Vol.8 (7), p.e1001058-e1001058</ispartof><rights>COPYRIGHT 2011 Public Library of Science</rights><rights>2011 Ioannidis, Garber. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited: Ioannidis JPA, Garber AM (2011) Individualized Cost-Effectiveness Analysis. PLoS Med 8(7): e1001058. doi:10.1371/journal.pmed.1001058</rights><rights>Ioannidis, Garber. 2011</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c763t-e88fc4f14b2fcb7c20913801ec589fe69bebc2b168a61049e3dc37a80e88e37b3</citedby><cites>FETCH-LOGICAL-c763t-e88fc4f14b2fcb7c20913801ec589fe69bebc2b168a61049e3dc37a80e88e37b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1288093577/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1288093577?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21765810$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ioannidis, John P A</creatorcontrib><creatorcontrib>Garber, Alan M</creatorcontrib><title>Individualized cost-effectiveness analysis</title><title>PLoS medicine</title><addtitle>PLoS Med</addtitle><description>[...]randomized trials and other clinical studies typically feed their data into decision and cost-effectiveness models. [...]the granularity of the cost and outcomes per patient may be important to convey, i.e., specifying separately the different outcomes, so that clinicians and patients may be better informed and able to make better choices. Erroneous inferences may result from unrealistic modeling of the decision process or unrealistic estimates for the various benefits, harms, and costs. [...]uncertainty in these values [42] or even in risk aversion [43] should not be underestimated.</description><subject>Analysis</subject><subject>Colds</subject><subject>Cost benefit analysis</subject><subject>Cost-Benefit Analysis - methods</subject><subject>Costs</subject><subject>Decision Making</subject><subject>Health aspects</subject><subject>Health Care Costs</subject><subject>Humans</subject><subject>Immunization</subject><subject>Intervention</subject><subject>Medical care, Cost of</subject><subject>Medicine</subject><subject>Models, Econometric</subject><subject>Population</subject><subject>Social and Behavioral Sciences</subject><subject>Social aspects</subject><subject>Studies</subject><subject>Treatment outcome</subject><issn>1549-1676</issn><issn>1549-1277</issn><issn>1549-1676</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqVk9tq3DAQhk1padK0b1DaQKGlBW81lizJN4UQelgIDfR0K2R57NWitTaWvSR5-mq7TliXvWjRhcTo-_8ZaZgkeQ5kBlTA-6Ufula72XqF1QwIAZLLB8kx5KxIgQv-cO98lDwJYUlIVpCCPE6OMhA8l0COk3fztrIbWw3a2VusTo0PfYp1jaa3G2wxhFMds9wEG54mj2rtAj4b95Pk56ePP86_pBeXn-fnZxepEZxGsZS1YTWwMqtNKUxGCqCSAJpcFjXyosTSZCVwqTkQViCtDBVakihEKkp6krzc-a6dD2p8ZlCQSUkKmgsRifmOqLxeqnVnV7q7UV5b9Sfgu0bprrfGoaIxqcjAcAqMZcJIiiWRVayFSykLE70-jNmGMv6kwbbvtJuYTm9au1CN3ygKlDHOosGb0aDzVwOGXq1sMOicbtEPQUkhCYWMkUi--os8_LiRanSs37a1j2nN1lOdZZwKmQsJkUoPUE3sWKzRt1jbGJ7wswN8XBWurDkoeDsRRKbH677RQwhq_v3bf7Bf_529_DVlX--xC9SuXwTvht76NkxBtgNN50PosL7vHxC1nZa7n1bbaVHjtETZi_3e34vuxoP-BvQsDDs</recordid><startdate>20110701</startdate><enddate>20110701</enddate><creator>Ioannidis, John P A</creator><creator>Garber, Alan M</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISN</scope><scope>ISR</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><scope>CZK</scope></search><sort><creationdate>20110701</creationdate><title>Individualized cost-effectiveness analysis</title><author>Ioannidis, John P A ; Garber, Alan M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c763t-e88fc4f14b2fcb7c20913801ec589fe69bebc2b168a61049e3dc37a80e88e37b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Analysis</topic><topic>Colds</topic><topic>Cost benefit analysis</topic><topic>Cost-Benefit Analysis - methods</topic><topic>Costs</topic><topic>Decision Making</topic><topic>Health aspects</topic><topic>Health Care Costs</topic><topic>Humans</topic><topic>Immunization</topic><topic>Intervention</topic><topic>Medical care, Cost of</topic><topic>Medicine</topic><topic>Models, Econometric</topic><topic>Population</topic><topic>Social and Behavioral Sciences</topic><topic>Social aspects</topic><topic>Studies</topic><topic>Treatment outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ioannidis, John P A</creatorcontrib><creatorcontrib>Garber, Alan M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Canada</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest_Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest - Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><collection>PLoS Medicine</collection><jtitle>PLoS medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ioannidis, John P A</au><au>Garber, Alan M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Individualized cost-effectiveness analysis</atitle><jtitle>PLoS medicine</jtitle><addtitle>PLoS Med</addtitle><date>2011-07-01</date><risdate>2011</risdate><volume>8</volume><issue>7</issue><spage>e1001058</spage><epage>e1001058</epage><pages>e1001058-e1001058</pages><issn>1549-1676</issn><issn>1549-1277</issn><eissn>1549-1676</eissn><abstract>[...]randomized trials and other clinical studies typically feed their data into decision and cost-effectiveness models. [...]the granularity of the cost and outcomes per patient may be important to convey, i.e., specifying separately the different outcomes, so that clinicians and patients may be better informed and able to make better choices. Erroneous inferences may result from unrealistic modeling of the decision process or unrealistic estimates for the various benefits, harms, and costs. [...]uncertainty in these values [42] or even in risk aversion [43] should not be underestimated.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>21765810</pmid><doi>10.1371/journal.pmed.1001058</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1549-1676
ispartof PLoS medicine, 2011-07, Vol.8 (7), p.e1001058-e1001058
issn 1549-1676
1549-1277
1549-1676
language eng
recordid cdi_plos_journals_1288093577
source NCBI_PubMed Central（免费）; ProQuest - Publicly Available Content Database
subjects Analysis
Colds
Cost benefit analysis
Cost-Benefit Analysis - methods
Costs
Decision Making
Health aspects
Health Care Costs
Humans
Immunization
Intervention
Medical care, Cost of
Medicine
Models, Econometric
Population
Social and Behavioral Sciences
Social aspects
Studies
Treatment outcome
title Individualized cost-effectiveness analysis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T03%3A49%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Individualized%20cost-effectiveness%20analysis&rft.jtitle=PLoS%20medicine&rft.au=Ioannidis,%20John%20P%20A&rft.date=2011-07-01&rft.volume=8&rft.issue=7&rft.spage=e1001058&rft.epage=e1001058&rft.pages=e1001058-e1001058&rft.issn=1549-1676&rft.eissn=1549-1676&rft_id=info:doi/10.1371/journal.pmed.1001058&rft_dat=%3Cgale_plos_%3EA263785781%3C/gale_plos_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c763t-e88fc4f14b2fcb7c20913801ec589fe69bebc2b168a61049e3dc37a80e88e37b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1288093577&rft_id=info:pmid/21765810&rft_galeid=A263785781&rfr_iscdi=true